# US 2020/0368208 A1 · Protein Translation Inhibitors and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368208 A1
- Document ID: US20200368208A1
- Status: Published application
- Kind: A1
- Application number: 16/879,226
- Filed: 2020-05-20
- Published: 2020-11-26
- Earliest claimed: 2019-05-23
- Assignees: University of Baltimore, Maryland
- Inventors: France Carrier; Alexander D. MacKerell; David J. Weber; Wenbo Yu
- Web page: https://patentgrep.com/patent/US20200368208A1

## CPC

- A61K 31/426: 1,3-Thiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are protein translation inhibitors and pharmaceutical compositions thereof that bind to an RNA Recognition motif in heterogeneous ribonucleoprotein A18 to inhibit binding to mRNA transcripts thereby inhibiting protein synthesis. Also provided is a method for treating a cancer by administering a pharmaceutically acceptable amounts of at least one of the protein translation inhibitors.

## Claims

### Claim 1

A protein translation inhibitor, comprising:
a compound with a chemical structure that binds to an RNA Recognition motif in a heterogeneous ribonucleoprotein A18.

### Claim 2 (depends on 1)

The protein translation inhibitor of claim 1, wherein the compound is

### Claim 3 (depends on 1)

The protein translation inhibitor of claim 1, wherein the compound is

### Claim 4 (depends on 1)

The protein translation inhibitor of claim 1, wherein the compound is

### Claim 5 (depends on 1)

The protein translation inhibitor of claim 1, wherein the compound is

### Claim 6 (depends on 1)

The protein translation inhibitor of claim 1, wherein the compound is

### Claim 7 (depends on 1)

The protein translation inhibitor of claim 1, wherein the compound is

### Claim 8 (depends on 1)

The protein translation inhibitor of claim 1, wherein the compound inhibits binding of the heterogeneous ribonucleoprotein A18 to an mRNA transcript for a protein associated with cancer cell proliferation.

### Claim 9 (depends on 8)

The protein translation inhibitor of claim 8, wherein the protein associated with cancer cell proliferation is thioredoxin, vascular endothelial growth factor, or replication protein A or a combination thereof.

### Claim 10 (depends on 1)

The protein translation inhibitor of claim 1, wherein the compound inhibits binding of the heterogeneous ribonucleoprotein A18 to an mRNA transcript for a tumor immune checkpoint protein.

### Claim 11 (depends on 10)

The protein translation inhibitor of claim 10, wherein the tumor immune checkpoint protein is cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1, programmed death-ligand 1, or a combination thereof.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising the protein translation inhibitor of claim 1 and a pharmaceutically acceptable carrier.

### Claim 13

A method for treating a cancer in a subject in need thereof comprising the step of:
administering to the subject a therapeutically effective amount of a protein translation administering to the subject a therapeutically effective amount of a protein translation inhibitor, thereby inhibiting translation of a protein associated with the cancer.

### Claim 14 (depends on 1)

The method of claim 1, wherein the protein translation inhibitor is

### Claim 15 (depends on 1)

The method of claim 1, wherein the protein translation inhibitor is

### Claim 16 (depends on 1)

The method of claim 1, wherein the protein translation inhibitor is

### Claim 17 (depends on 1)

The method of claim 1, wherein the protein translation inhibitor is

### Claim 18 (depends on 1)

The method of claim 1, wherein the protein translation inhibitor is

### Claim 19 (depends on 1)

The method of claim 1, wherein the protein translation inhibitor is

### Claim 20 (depends on 13)

The method of claim 13, wherein the cancer is a melanoma, a lung cancer, a prostate cancer, an intestinal cancer, a colon cancer, a pancreatic cancer, a gall bladder cancer, a bile duct cancer, a brain cancer, a glioblastoma, a breast cancer, a hepatocellular carcinoma, a kidney cancer, a bladder cancer, or a lymphoma.
